Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Besaratinia, A.
Right arrow Articles by Pfeifer, G. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Besaratinia, A.
Right arrow Articles by Pfeifer, G. P.
[Cancer Research 62, 4331-4338, August 1, 2002]
© 2002 American Association for Cancer Research


Carcinogenesis

Mutational Signature of the Proximate Bladder Carcinogen N-Hydroxy-4-acetylaminobiphenyl

Inconsistency with the p53 Mutational Spectrum in Bladder Cancer1

Ahmad Besaratinia2, Steven E. Bates and Gerd P. Pfeifer

Department of Biology, Beckman Research Institute of the City of Hope, Duarte, California 91010

We studied the mutagenicity of the proximate bladder carcinogen, N-hydroxy-4-acetylaminobiphenyl (N-OH-AABP) in embryonic fibroblasts of the Big Blue mouse. Treatment of these cells with increasing concentrations of N-OH-AABP for 24 h resulted in a dose-dependent increase in mutation frequency of the cII transgene up to 12.8-fold over the background. Single base substitutions comprised 86% of the N-OH-AABP-induced mutations and 74% of the spontaneous cII mutations (sequenced number of mutant plaques, 141 and 145, respectively). Of these, 63 and 36%, respectively, occurred at guanine residues along the cII gene. Whereas G to T transversions predominated in the induced cII mutations (47%), insertion was the most spontaneously derived cII mutation (19%). Mapping of N-OH-AABP-induced DNA adducts along the cII gene by terminal transferase-dependent PCR showed the formation of DNA adducts at specific nucleotide positions. Five preferential DNA adduction sites were established, of which four were major mutation sites for N-OH-AABP, especially for G to T transversions. This unique mutational signature of N-OH-AABP in the cII gene was, however, in sharp contrast with the mutational spectrum of the p53 gene in human bladder cancer. G to A transitions are the dominant type of p53 mutations (53%), being also prevalent in almost all of its five mutational hotspots (codons 175, 248, 273, 280, and 285). In addition, the majority of mutations in three of these hotspots (codons 175, 248, and 273) are at a methylated CpG site, whereas in the cII gene neither the preferential N-OH-AABP DNA adduction sites nor the induced mutational hotspots are biased toward methylated CpG dinucleotides. We conclude that N-OH-AABP leaves a characteristic mutational signature in the cII transgene, which is consistent with its preferential DNA adduction profile. However, the pattern of mutation induced by N-OH-AABP in the cII gene is largely at odds with the mutational spectrum of the p53 gene in human bladder cancer.




This article has been cited by other articles:


Home page
FASEB J.Home page
A. Besaratinia, S.-i. Kim, and G. P. Pfeifer
Rapid repair of UVA-induced oxidized purines and persistence of UVB-induced dipyrimidine lesions determine the mutagenicity of sunlight in mouse cells
FASEB J, July 1, 2008; 22(7): 2379 - 2392.
[Abstract] [Full Text] [PDF]


Home page
MutagenesisHome page
D.-H. Lee and G. P. Pfeifer
Mutagenesis induced by the nitric oxide donor sodium nitroprusside in mouse cells
Mutagenesis, January 1, 2007; 22(1): 63 - 67.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
J. v. Brocke, H. H. Schmeiser, M. Reinbold, and M. Hollstein
MEF immortalization to investigate the ins and outs of mutagenesis
Carcinogenesis, November 1, 2006; 27(11): 2141 - 2147.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
H. Wallerand, A. A. Bakkar, S. G. D. de Medina, J.-C. Pairon, Y.-C. Yang, D. Vordos, H. Bittard, S. Fauconnet, J.-C. Kouyoumdjian, M.-C. Jaurand, et al.
Mutations in TP53, but not FGFR3, in urothelial cell carcinoma of the bladder are influenced by smoking: contribution of exogenous versus endogenous carcinogens
Carcinogenesis, January 1, 2005; 26(1): 177 - 184.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J.-H. Yoon, A. Besaratinia, Z. Feng, M.-s. Tang, S. Amin, A. Luch, and G. P. Pfeifer
DNA Damage, Repair, and Mutation Induction by (+)-Syn and (-)-Anti-Dibenzo[a,l]Pyrene-11,12-Diol-13,14-Epoxides in Mouse Cells
Cancer Res., October 15, 2004; 64(20): 7321 - 7328.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
A. Besaratinia and G. P. Pfeifer
Genotoxicity of Acrylamide and Glycidamide
J Natl Cancer Inst, July 7, 2004; 96(13): 1023 - 1029.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. Besaratinia and G. P. Pfeifer
Enhancement of the Mutagenicity of Benzo(a)pyrene Diol Epoxide by a Nonmutagenic Dose of Ultraviolet A Radiation
Cancer Res., December 15, 2003; 63(24): 8708 - 8716.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
L. E. Moore, A. H. Smith, C. Eng, S. DeVries, D. Kalman, V. Bhargava, K. Chew, C. Ferreccio, O. A. Rey, C. Hopenhayn, et al.
P53 alterations in bladder tumors from arsenic and tobacco exposed patients
Carcinogenesis, November 1, 2003; 24(11): 1785 - 1791.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
A. Besaratinia and G. P. Pfeifer
Weak Yet Distinct Mutagenicity of Acrylamide in Mammalian Cells
J Natl Cancer Inst, June 18, 2003; 95(12): 889 - 896.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2002 by the American Association for Cancer Research.